

BIOCON GROUP

FACT SHEET

March - 2016

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		(Rs Crore)
	March 31, 2016	March 31, 2015
EQUITY AND LIABILITIES		
Shareholder's Funds		
(a) Share capital	100	100
(b) Reserves and surplus	3,956	3,171
	4,056	3,271
Minority interest	311	172
Non-current liabilities		
(a) Long-term borrowings	2,072	770
(b) Deferred tax liability (net)	35	42
(c) Other long-term liabilities	350	552
(d) Long-term provisions	30	15
	2,487	1,379
Current liabilities		
(a) Short-term borrowings	395	261
(b) Trade payables	547	429
(c) Other current liabilities	598	706
(d) Short-term provisions	88	158
	1,628	1,554
TOTAL	8,482	6,376
ASSETS		
Non-current assets		
(a) Fixed assets	3,885	3,280
(b) Goodwill	26	26
(c) Long term loans and advances	412	369
(d) Other non-current assets	166	137
	4,489	3,812
Current assets		
(a) Current Investments	429	230
(b) Inventories	511	453
(c) Trade receivables	823	771
(d) Cash and cash equivalents	1,921	938
(e) Short term loans and advances	185	76
(f) Other current assets	124	96
	3,993	2,564
TOTAL	8,482	6,376

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs Crore)
Particulars	FY 16	FY 15	Variance
INCOME			
Biopharmaceuticals	2,391	2,236	7%
Biopharma *	1,954	1,806	8%
Branded formulations - India	437	430	2%
Contract research	1,060	823	29%
Total Sales	3,451	3,059	13%
Other income	119	84	42%
TOTAL REVENUE	3,570	3,143	14%
EXPENDITURE			
Material & Power costs	1,486	1,423	4%
Staff costs	585	493	19%
Research & Development **	275	169	63%
Other expenses	321	309	3%
Manufacturing, staff & other expenses	2,667	2,394	
EBITDA	903	749	21%
Interest & Finance charges	10	9	15%
Depreciation & Amortisation	242	221	10%
PBT BEFORE EXCEPTIONAL ITEM	651	519	26%
Exceptional item, Net	576	105	447%
PBT	1,227	624	97%
Taxes	140	96	
Taxes on exceptional item	117	-	
NET PROFIT BEFORE MINORITY INTEREST	970	528	84%
Minority interest	74	31	
NET PROFIT FOR THE PERIOD	896	497	80%
EPS Rs.	44.8	24.8	
<i>Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers</i>			
<i>* Biopharma Income includes:</i>			
Licensing Income	76	43	
<i>** Gross Research & Development expenses</i>	427	329	130%

FY 15 - Tax incidence in the hands of BRL on the sale of shares has been fully offset against business losses of BRL. BRL had created deferred tax asset of Rs 10 as at December 31, 2014 which has been utilised on consummation of sale.

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crore)
Particulars	Q4 FY 16	Q4 FY 15	Variance
INCOME			
Biopharmaceuticals	655	592	11%
Biopharma *	554	494	12%
Branded formulations - India	101	98	3%
Contract research	316	238	32%
Total Sales	971	830	17%
Other income	33	24	38%
TOTAL REVENUE	1,004	854	17%
EXPENDITURE			
Material & Power costs	402	376	7%
Staff costs	161	126	28%
Research & Development **	100	56	78%
Other expenses	103	94	10%
Manufacturing, staff & other expenses	766	652	
EBITDA	238	202	18%
Interest & Finance charges	1	0	
Depreciation & Amortisation	63	59	7%
PBT BEFORE EXCEPTIONAL ITEM	174	143	21%
Exceptional item, Net	268	105	155%
PBT	442	248	78%
Taxes	46	22	
Taxes on exceptional item	12	10	
NET PROFIT BEFORE MINORITY INTEREST	384	216	77%
Minority interest	23	15	
NET PROFIT FOR THE PERIOD	361	201	79%
EPS Rs.	18.0	10.0	
<i>Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers</i>			
<i>* Biopharma Income includes:</i>			
<i>Licensing Income</i>	23	5	
<i>** Gross Research & Development expenses</i>	152	100	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs Crore)
Particulars	Q4 FY 16	Q3 FY 16	Variance
<u>INCOME</u>			
Biopharmaceuticals	655	558	17%
Biopharma *	554	454	22%
Branded formulations - India	101	104	-3%
Contract research	316	270	17%
Total Sales	971	828	17%
Other income	33	29	16%
TOTAL REVENUE	1,004	857	17%
<u>EXPENDITURE</u>			
Material & Power costs	402	353	14%
Staff costs	161	146	10%
Research & Development **	100	68	47%
Other expenses	103	81	28%
Manufacturing, staff & other expenses	766	648	
EBITDA	238	209	14%
Interest & Finance charges	1	2	-7%
Depreciation & Amortisation	63	62	1%
PBT BEFORE EXCEPTIONAL ITEM	174	145	20%
Exceptional item, net	268	-	
PBT	442	145	204%
Taxes	46	24	
Taxes on exceptional item	12	-	
NET PROFIT BEFORE MINORITY INTEREST	384	121	217%
Minority interest	23	18	
NET PROFIT FOR THE PERIOD	361	103	250%
EPS Rs.	18.0	5.2	
<i>Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	23	32	
** Gross Research & Development expenses	152	91	